BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...